Literature DB >> 19689352

Are the pleiotropic effects of telmisartan clinically relevant?

C V Rizos1, M S Elisaf, E N Liberopoulos.   

Abstract

Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and favorable safety profile. Telmisartan, a member of the ARB family, holds some additional traits which differentiate it from the rest ARBs. A pivotal role in these characteristics plays its ability to partially activate the peroxisome proliferator activated receptor-gamma, which in turn controls a number of metabolism-related genes. Indeed, telmisartan has shown a number of pleiotropic effects in experimental and clinical studies. These include the amelioration of insulin resistance, improvement of lipid profile and favorable fat redistribution. Moreover, telmisartan has been associated with beneficial effects on vascular function, cardiac remodeling and renal function. However, do all these pleiotropic effects translate into clinical benefit? Recent studies have tried to answer this question with promising but not definitive results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689352     DOI: 10.2174/138161209788923859

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

Review 1.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Lipid effects of antihypertensive medications.

Authors:  Roderick Deano; Matthew Sorrentino
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 3.  Telmisartan: a review of its use in cardiovascular disease prevention.

Authors:  James E Frampton
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 4.  Vascular effects of antihypertensive drug therapy.

Authors:  Asia Rehman; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

5.  Modulation of lipid metabolic defects rescues cleft palate in Tgfbr2 mutant mice.

Authors:  Junichi Iwata; Akiko Suzuki; Richard C Pelikan; Thach-Vu Ho; Pedro A Sanchez-Lara; Yang Chai
Journal:  Hum Mol Genet       Date:  2013-08-23       Impact factor: 6.150

6.  Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.

Authors:  Marta H Krieger; Annarita Di Lorenzo; Christine Teutsch; Katalin Kauser; William C Sessa
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

7.  Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.

Authors:  Sang-Hyun Ihm; Hui-Kyung Jeon; Tae-Joon Cha; Taek-Jong Hong; Sang-Hyun Kim; Nae-Hee Lee; Jung Han Yoon; Namsik Yoon; Kyung-Kuk Hwang; Sang-Ho Jo; Ho-Joong Youn
Journal:  Drug Des Devel Ther       Date:  2016-11-23       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.